OLARIF E/D ™
OLARIF 5 ML EYE DROPS | |
---|---|
Generic : | Olopatadine 0.1% |
Thearapeutic : | Ophthalmic |
Pack Size : | 5 ml |
Strength : | |
Dosage Form : | Eye Drop |
Olarif
Olopatadine 0.1%
Sterile and Pyrogen Free Eye Drops
Composition
- Each ml contains Olopatadine Hydrochloride USP equivalent to Olopatadine 1 mg, Preservative: Benzalkonium Chloride BP 0.1 mg.
Description
- It is a sterile and pyrogen-free ophthalmic solution containing Olopatadine Hydrochloride, a relatively selective H1-receptor antagonist and mast cell stabilizer for topical administration to the eyes.
Clinical Pharmacology
Olopatadine inhibits the release of histamine from the mast cell and is a relatively selective histamine H1-antagonist that inhibits the in vivo and in vitro type 1 immediate hypersensitivity reaction including inhibition of histamine-induced effects on human conjunctival epithelial cells. Olopatadine has no effects on alpha-adrenergic, dopamine, and muscarinic type 1 and 2 receptors. Olopatadine was shown to have low systemic exposure after topical administration.
Indications and Usage
These eye drops are indicated for the treatment of signs and symptoms (itchy, watery, red, and swollen eyes and/or eyelids) of allergic conjunctivitis including vernal keratoconjunctivitis, vernal keratitis, blepharitis, blepharoconjunctivitis and giant papillary conjunctivitis.
Dosage and Administration
- The recommended dose is 1 drop in the affected eye(s) two times daily.
Contraindications
- It is contraindicated in persons with a known hypersensitivity to any component of this product.
Precautions
Patients should be advised not to wear a contact lens if their eye is red. Olopatadine ophthalmic solution should not be used to treat contact lens-related irritation. Benzalkonium Chloride, the preservative of this drop, may be absorbed by soft contact lenses. Patients who wear soft contact lenses and whose eyes are not red should be instructed to wait at least 10 minutes after installation of these eye drops before they insert their contact lenses. The treatment should be discontinued in the presence of an allergic reaction.
Side-Effects
Rarely headaches have been reported. Other adverse effects: asthenia, blurred vision, burning or stinging, cold syndrome, dry eye, foreign body sensation, hyperemia, hypersensitivity, keratitis, lid edema, nausea, pharyngitis, pruritus, rhinitis, sinusitis, and taste perversion.
Use in Pregnancy & Lactation
Olopatadine was found not to be teratogenic in rats and rabbits. There are, however, no adequate and well-controlled studies in pregnant women. This drug should be used in pregnant women only if the potential benefit justifies the potential risk to the fetus. It is not known whether topical ocular administration could result in sufficient systemic absorption to produce detectable quantities of human breast milk. Nevertheless, caution should be exercised when olopatadine is administered to a nursing mother.
Drug Interactions
- Specific drug interaction studies have not been conducted with Olopatadine ophthalmic solution.
Overdosage
- There is no information on Olopatadine overdose. However, excessive use of any medication can have serious consequences. If you suspect an overdose, seek medical attention without delay.
Pharmaceutical Precautions
- Store at room temperature and protect from light. It is desirable that the contents should not be used more than one month after the first opening of the bottle.
Commercial Pack
- Plastic dropper bottle of 5 ml.
Biopharma Ltd. Produces OLARIF 5 ML EYE DROPS it is a trusted product for alleviating various discomforts, and it's commonly found in pharmacies and stores.